A dual altered peptide ligand down-regulates myasthenogenic T cell responses and reverses experimental autoimmune myasthenia gravis via up-regulation of Fas-FasL-mediated apoptosis

Immunology

Volumn 118, Issue 3, 2006, Pages 413-424

  Aruna, Badiga Venkata ^a   Ben David, Hava ^a   Sela, Michael ^a   Mozes, Edna ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Apoptosis; Dual APL; Experimental autoimmune myasthenia gravis (EAMG); Fas FasL; Immunosuppression

Indexed keywords

CASPASE 3; CASPASE 8; CD4 ANTIGEN; CHOLINERGIC RECEPTOR; DUAL ALTERED PEPTIDE LIGAND; FAS ANTIGEN; FAS LIGAND; FLICE INHIBITORY PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE P38; PEPTIDE DERIVATIVE; PROTEIN BCL 2; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; FEMALE; IMMUNOMODULATION; MOUSE; MYASTHENIA GRAVIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANNEXIN A5; ANTIGENS, CD95; APOPTOSIS; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CASPASE 8; CASPASES; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE; DOWN-REGULATION; FAS LIGAND PROTEIN; FEMALE; IMMUNIZATION; IMMUNOTHERAPY; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIGANDS; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; MYASTHENIA GRAVIS, AUTOIMMUNE, EXPERIMENTAL; PEPTIDE FRAGMENTS; RECEPTORS, CHOLINERGIC; RECEPTORS, INTERLEUKIN-2; T-LYMPHOCYTE SUBSETS; TUMOR NECROSIS FACTORS; UP-REGULATION;

EID: 33745221626     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2006.02398.x     Document Type: Article

References (43)

1. Lindstrom J Shelton D Fuji Y. Myasthenia gravis. Adv Immunol 1988 42 : 233 84.
2. Drachman DB. Medical progress: myasthenia gravis. N Engl J Med 1994 330 : 1797 810.
3. Brocke S Brautbar C Steinman L Abramsky O Rothbard J Neumann D Fuchs S Mozes E. In vitro proliferative responses and antibody titers specific to human acetylcholine receptor synthetic peptides in patients with myasthenia gravis and relation to HLA class II genes. J Clin Invest 1988 82 : 1894 900.
4. Karni A Zisman E Katz-Levy Y et al. Reactivity of T cells from seronegative patients with myasthenia gravis to T cell epitopes of the human acetylcholine receptor. Neurology 1997 48 : 1638 42.
5. Brocke S Dayan M Rothbard J Fuchs S Mozes E. The autoimmune response of different mouse strains to T-cell epitopes of the human acetylcholine receptor alpha subunit. Immunology 1990 69 : 495 500.
6. Kirshner SL Katz-Levy Y Wirguin I Argov Z Mozes E. Fine specificity of T-cell lines and clones that are capable of inducing autoimmune manifestations in mice. Cell Immunol 1994 157 : 11 28.
7. Katz-Levy Y Paas-Rozner M Kirshner S et al. A peptide composed of tandem analogs of two myasthenogenic T cell epitopes interferes with specific autoimmune responses. Proc Natl Acad Sci USA 1997 94 : 3200 5.
8. Paas-Rozner M Dayan M Paas Y Changeux J-P Wirguin I Sela M Mozes E. Oral administration of two myasthenogenic T cell epitopes down-regulates experimental autoimmune myasthenia gravis in mice. Proc Natl Acad Sci USA 2000 97 : 2168 73.
9. Paas-Rozner M Sela M Mozes E. The nature of the active suppression of responses associated with experimental autoimmune myasthenia gravis by a dual altered peptide ligand administered by different routes. Proc Natl Acad Sci USA 2001 98 : 12642 7.
10. Faber-Elmann A Paas-Rozner M Sela M Mozes E. Altered peptide ligands act as partial agonists by inhibiting phospholipase C activity induced by myasthenogenic T cell epitopes. Proc Natl Acad Sci USA 1998 95 : 14320 5.
11. Faber-Elmann A Grabovsky V Dayan M Sela M Alon R Mozes E. Cytokine profile and T cell adhesiveness to endothelial selectins: in vivo induction by a myasthenogenic T cell epitope and immunomodulation by a dual altered peptide ligand. Int Immunol 2000 12 : 1651 8.
12. Paas-Rozner M Sela M Mozes E. A dual altered peptide ligand down-regulates myasthenogenic T cell responses by up-regulating CD25- and CTLA-4-expressing CD4+ T cells. Proc Natl Acad Sci USA 2003 100 : 6676 81.
13. Sakaguchi S Sakaguchi N Shimizu J et al. Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 2001 182 : 18 32.
14. Shevach EM. Certified professionals: CD4(+) CD25(+) suppressor T cells. J Exp Med 2001 193 : F41 5.
15. Aruna BV Sela M Mozes E. Suppression of rnyasthenogenic responses of a T cell line by a dual altered peptide ligand by induction of CD4(+) CD25(+) regulatory cells. Proc Natl Acad Sci USA 2005 102 : 10285 90.
16. Ben-David H Sela M Mozes E. Down-regulation of myasthenogenic T cell responses by a dual altered peptide ligand via CD4(+) CD25(+)-regulated events leading to apoptosis. Proc Natl Acad Sci USA 2005 102 : 2028 33.
17. Krammer PH. CD95's deadly mission in the immune system. Nature 2000 407 : 789 95.
18. Davidson WF Haudenschild C Kwon J Williams MS. T cell receptor ligation triggers novel nonapoptotic cell death pathways that are Fas-independent or Fas-dependent. J Immunol 2002 169 : 6218 30.
19. Zhang J Gao JX Salojin K Shao Q Grattan M Meagher C Laird DW Delovitch TL. Regulation of Fas ligand expression during activation-induced cell death in T cells by p38 mitogen-activated protein kinase and c-Jun NH2-terminal kinase. J Exp Med 2000 191 : 1017 30.
20. Masunaga A Arai T Yoshitake T Itoyama S Sugawara I. Reduced expression of apoptosis-related antigens in thymuses from patients with myasthenia gravis. Immunol Lett 1994 39 : 169 72.
21. Nagata T Onodera H Ohuchi M et al. Decreased expression of c-myc family genes in thymuses from myasthenia gravis patients. J Neuroimmunol 2001 115 : 199 202.
22. Salakou S Tsamandas AC Bonikos DS Papapetropoulos T Dougenis D. The potential role of bcl-2, bax, and Ki67 expression in thymus of patients with myasthenia gravis, and their correlation with clinicopathologic parameters. Eur J Cardiothorac Surg 2001 20 : 712 21.
23. Elliott J Blanchard SG Wu W et al. Purification of Torpedo californica post-synaptic membranes and fractionation of their constituent proteins. Biochem J 1980 185 : 667 77.
24. Axelrod O Mozes E. Analysis of the biological functions and fine specificity of (T,G)-A-L specific T cell clones. Immunobiology 1986 172 : 99 109.
25. Rieux-Laucat F Le Deist F Hivroz C Roberts IA Debatin KM Fischer A de Villartay JP. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science 1995 268 : 1347 9.
26. Du Y Zhang QY Ruan LR Liang CC Li QR He W. The relationship between abnormal apoptosis and Fas expression of thymocytes from patients with myasthenia gravis. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2003 19 : 450 3.
27. Deng C Goluszko E Christadoss P. Fas/Fas ligand pathway, apoptosis, and clonal anergy involved in systemic acetylcholine receptor T cell epitope tolerance. J Immunol 2001 166 : 3458 67.
28. Refaeli Y Van Parijs L London CA Tschopp J Abbas AK. Biochemical mechanisms of IL-2-regulated Fas-mediated T cell apoptosis. Immunity 1998 8 : 615 23.
29. Papiernik M. Natural CD4+ CD25+ regulatory T cells. Their role in the control of superantigen responses. Immunol Rev 2001 182 : 180 9.
30. Chen J-J Sun Y Nabel GJ. Regulation of the proinflammatory effects of Fas ligand (CD95L). Science 1998 282 : 1714 17.
31. Janssens W Carlier V Wu B VanderElst L Jacquemin MG Saint-Remy JM. CD4+CD25+ T cells lyse antigen-presenting B cells by Fas-Fas ligand interaction in an epitope-specific manner. J Immunol 2003 171 : 4604 12.
32. Cavinato RA Casiraghi F Azzollini N et al. Pretransplant donor peripheral blood mononuclear cells infusion induces transplantation tolerance by generating regulatory T cells. Transplant 2005 79 : 1034 9.
33. + T cells expressing CD95 ligand and secreting IL-4 in the liver. J Immunol 2002 168 : 2188 99.
34. Aung S Graham BS. IL-4 diminishes perforin-mediated and increases Fas ligand-mediated cytotoxicity in vivo. J Immunol 2000 164 : 3487 93.
35. Barreiro R Luker G Herndon J Ferguson TA. Termination of antigen-specific immunity by CD95 ligand (Fas ligand) and IL-10. J Immunol 2004 173 : 1519 25.
36. Ebert EC. IL-15 converts human intestinal intraepithelial lymphocytes to CD94 producers of IFN-gamma and IL-10, the latter promoting Fas ligand-mediated cytotoxicity. Immunology 2005 115 : 118 26.
37. Lundy SK Boros DL. Fas ligand-expressing B-1a lymphocytes mediate CD4(+)-T-cell apoptosis during schistosomal infection. induction by interleukin 4 (IL-4) and IL-10. Infect Immun 2002 70 : 812 19.
38. Chun HJ Zheng L Ahmad M et al. Pleiotropic defects in lymphocyte activation caused by caspase-8 mutations lead to human immunodeficiency. Nature 2002 419 : 395 9.
39. Wasem C Arnold D Saurer L et al. Sensitizing antigen-specific CD8+ T cells for accelerated suicide causes immune incompetence. J Clin Invest 2003 111 : 1191 9.
40. Budd RC. Death receptors couple to both cell proliferation and apoptosis. J Clin Invest 2002 109 : 437 42.
41. Gallagher SF Peng Y Haines K Baksh K Epling-Burnette PK Yang J Murr MM. Fas/FasL play a central role in pancreatitis-induced hepatocyte apoptosis. J Gastrointest Surg 2005 9 : 467 74.
42. Perlman R Schiemann WP Brooks MW Lodish HF Weinberg RA. TGF-beta-induced apoptosis is mediated by the adapter protein Daxx that facilitates JNK activation. Nat Cell Biol 2001 3 : 708 14.
43. Sanchez-Capelo A. Dual role for TGF-beta1 in apoptosis. Cytokine Growth Factor Rev 2005 16 : 15 34.